Browsing Tag
Erasca Inc.
1 post
Erasca’s $6.2bn valuation faces bigger test as ERAS-0015 heads toward three pivotal trials
ERAS-0015 wins FDA Fast Track status as Erasca deploys nearly $1bn behind three planned pivotal cancer trials after an early 57% response signal.